Drug Profile
Osimertinib companion diagnostic - AstraZeneca/Roche
Alternative Names: cobas EGFR Mutation Test v2 (US-IVD); Mereletinib companion diagnostic - AstraZeneca/RocheLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator AstraZeneca; Roche
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Non-small cell lung cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Diagnosis) in Switzerland
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Diagnosis) in United Kingdom
- 18 Apr 2018 US FDA approves Premarket supplement application for Osimertinib companion diagnostic for first-line treatment of patients with Non-small cell lung cancer (Diagnosis) in USA